Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OSMITROL 15% IN WATER vs MANNITOL 10%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Osmotic diuretic; increases plasma osmolality, drawing water from extravascular to intravascular space, thereby reducing intracranial and intraocular pressure.
Mannitol is an osmotic diuretic that increases urinary output by raising the osmolarity of glomerular filtrate, thereby reducing tubular reabsorption of water and solutes. It also reduces cerebral edema by creating an osmotic gradient across the blood-brain barrier, drawing water from brain tissue into plasma.
Reduction of intracranial pressure,Reduction of intraocular pressure,Promotion of diuresis in oliguric acute renal failure before irreversible renal failure occurs
Reduction of intracranial pressure and cerebral edema,Promotion of diuresis in patients with acute renal failure (oliguric phase) or to prevent renal failure in certain conditions,Reduction of intraocular pressure in acute glaucoma,Enhancement of urinary excretion of toxic substances (e.g., in overdoses),Adjunct in dialysis or hemofiltration (off-label)
IV infusion of 50-200 g over 30-60 minutes as a 15% solution; typical adult dose is 1.5-2 g/kg every 6-8 hours.
0.25-2 g/kg intravenously as a 10% solution over 30-60 minutes, typically 50-100 g every 6-8 hours.
Terminal elimination half-life is approximately 0.25–1.5 hours in patients with normal renal function; prolonged to 24–36 hours in anuria or severe renal impairment.
Terminal half-life: 1.1–1.6 hours; prolonged to 6–36 hours in renal impairment
Minimal hepatic metabolism; excreted unchanged by the kidneys.
Mannitol is not metabolized in the body. It is eliminated unchanged by the kidneys via glomerular filtration with minimal tubular reabsorption.
Primarily renal excretion as unchanged drug; >97% eliminated by glomerular filtration within 24 hours. Minimal biliary/fecal elimination (<3%).
Renal: 90% as unchanged drug; <10% metabolized in liver to fructose and glucose; fecal: negligible
Negligible (<5%) protein binding; does not bind significantly to albumin or other plasma proteins.
Negligible (<2%); does not bind to plasma proteins
Volume of distribution is approximately 0.4–0.6 L/kg, confined primarily to extracellular fluid; little intracellular penetration.
0.36–0.5 L/kg; distributes primarily in extracellular fluid, limited CNS penetration due to hydrophilic nature
Not applicable (NA) due to intravenous administration only; oral bioavailability is negligible (not absorbed).
IV: 100%; oral: negligible (<10%) due to poor absorption and osmotic diarrhea
Contraindicated in anuria or severe renal impairment (e GFR < 10 m L/min); use with caution in mild to moderate impairment, monitor serum osmolarity and renal function.
Contraindicated in anuria or severe renal impairment (GFR < 20 m L/min). For GFR 20-50 m L/min, reduce dose by 50% and monitor serum osmolality.
No specific adjustment for Child-Pugh class; monitor for volume overload and electrolyte disturbances in severe hepatic impairment.
No specific Child-Pugh based adjustment required; use with caution in severe hepatic impairment due to risk of fluid overload.
IV infusion of 0.25-2 g/kg as a 15-20% solution over 30-60 minutes; dosing based on weight and clinical response.
0.25-1 g/kg intravenously as a 10% solution over 30-60 minutes, repeated every 6-8 hours as needed.
Start at lower end of dosing range; monitor for fluid overload, electrolyte imbalances, and renal function due to age-related decreased reserve.
Start at lower end of dosing range (0.25-0.5 g/kg) due to decreased renal function; monitor fluid and electrolyte balance closely.
None FDA-approved.
None
Renal toxicity with high doses or prolonged use,Congestive heart failure exacerbation due to volume expansion,Electrolyte disturbances (hyponatremia, hypokalemia),Rapid infusion may cause hypotension and seizures,Use with caution in patients with anuria or pre-existing renal disease
Use with caution in patients with congestive heart failure due to risk of pulmonary edema from fluid overload,Monitor serum electrolytes (especially sodium and potassium) and renal function during therapy,May cause acute kidney injury with excessive doses or pre-existing renal impairment,In patients with intracranial hemorrhage, avoid rapid reduction of intracranial pressure,May cause expansion of extracellular fluid volume leading to pulmonary edema in patients with compromised cardiac function
Anuria due to severe renal disease,Well-established anuria due to severe renal disease,Pulmonary congestion or edema,Active intracranial bleeding (except during craniotomy),Severe dehydration,Hypersensitivity to mannitol
Anuria due to severe renal disease,Severe pulmonary edema or congestion,Active intracranial bleeding (except during craniotomy),Severe dehydration,Hypersensitivity to mannitol
No specific food interactions are documented. However, patients should maintain adequate hydration unless contraindicated. Diets high in sodium may exacerbate hypernatremia risk. Monitor fluid and electrolyte intake as directed by the clinician.
Avoid high-sodium foods and salt substitutes to prevent electrolyte imbalance; maintain adequate fluid intake unless fluid restriction is advised; no specific food interactions, but monitor for changes in blood glucose if diabetic.
Osmitrol (mannitol) 15% in water is FDA pregnancy category C. Animal studies have not been conducted; no well-controlled human studies exist. Mannitol is a high-osmolar agent that can cause maternal osmotic diuresis and fluid/electrolyte disturbances, potentially affecting fetal homeostasis. Risk in first trimester is unknown; in second and third trimesters, use only if clearly needed due to potential for maternal pulmonary edema or heart failure.
Mannitol is a pregnancy category C drug. First trimester: Limited human data; animal studies indicate potential for fetal harm at high doses due to osmotic effects, but risk with clinical use is low. Second trimester: Generally safe for short-term use when indicated (e.g., elevated intracranial pressure), but avoid prolonged exposure to prevent fetal dehydration or electrolyte imbalances. Third trimester: Use cautiously; osmotic diuresis may cause maternal hypovolemia, potentially reducing placental perfusion and leading to fetal distress.
It is unknown if mannitol is excreted in breast milk. In lactating women, breast-feeding is not recommended during IV infusion of high-dose mannitol due to possible infant exposure to high osmolar load. M/P ratio not available.
Mannitol is excreted into breast milk in low concentrations (estimated M/P ratio <0.1) due to its high molecular weight and hydrophilicity. Oral bioavailability in infants is negligible, and no adverse effects have been reported. However, caution is advised if used repeatedly or in high doses, as theoretical risk of neonatal electrolyte imbalance exists.
No specific dose adjustments for pregnancy are established. Use with caution due to potential for altered renal function and fluid balance. Start with lowest effective dose, such as 50-100 g over 24 hours. Monitor closely for maternal volume overload.
Pregnancy does not significantly alter the pharmacokinetics of mannitol. Standard adult dosing (0.25–2 g/kg as a 10% solution) is recommended, with adjustments based on renal function, volume status, and therapeutic response. Avoid excessive doses to prevent maternal volume overload and electrolyte disturbances.
OSMITROL 15% IN WATER is a hypertonic solution for intravenous administration. Monitor serum sodium and osmolality closely to avoid hypernatremia and hyperosmolality. Ensure patency of IV line as extravasation can cause tissue necrosis. Use with caution in patients with renal impairment, heart failure, or hypovolemia. Rapid infusion can cause hemolysis. May cause osmotic diuresis leading to electrolyte depletion; monitor potassium and magnesium.
Administer via in-line filter to prevent crystallization; monitor serum sodium and osmolality closely to avoid hypernatremia and osmotic demyelination; ensure adequate urine output before use to avoid pulmonary edema; use with caution in patients with congestive heart failure or renal impairment; can cause transient volume expansion followed by diuresis.
This medication is given intravenously to reduce brain swelling or lower eye pressure.,Report any pain, redness, or swelling at the injection site immediately.,You may experience increased thirst or urination; this is expected due to the medication's effects.,Inform your healthcare provider if you have a history of kidney problems, heart failure, or dehydration.,Regular blood tests will be performed to monitor your electrolyte levels and kidney function.
This medication may cause increased thirst and frequent urination.,Report any chest pain, difficulty breathing, or swelling of ankles/legs.,Avoid consuming salty foods to prevent fluid retention.,Do not stop taking without consulting your doctor.,Inform your doctor if you have kidney disease, heart failure, or are on a low-salt diet.
No interactions on record
"Concomitant use of clonidine and mannitol may potentiate the hypotensive effect of clonidine, leading to an increased risk of severe hypotension, syncope, and orthostatic hypotension. Mannitol, an osmotic diuretic, can cause volume depletion and electrolyte disturbances, which may exacerbate clonidine's sympatholytic effects on blood pressure regulation. This interaction is particularly concerning in patients with pre-existing cardiovascular conditions or those receiving other antihypertensive agents."
"Mannitol, an osmotic diuretic, induces intravascular volume expansion followed by diuresis, which can cause electrolyte disturbances, particularly hypokalemia and hypomagnesemia. Nifedipine, a calcium channel blocker, can further lower blood pressure through vasodilation. The combination may enhance the hypotensive effect and increase the risk of arrhythmias due to electrolyte imbalances."
"Coadministration of candesartan cilexetil, an angiotensin II receptor blocker (ARB), with mannitol, an osmotic diuretic, can result in an additive hypotensive effect due to overlapping mechanisms that reduce blood pressure. Mannitol increases renal water excretion, decreasing plasma volume and preload, while candesartan inhibits angiotensin II-mediated vasoconstriction and aldosterone secretion, leading to vasodilation and reduced afterload. This combined effect may predispose patients to symptomatic hypotension, especially in those with volume depletion or renal impairment."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OSMITROL 15% IN WATER vs MANNITOL 10%, answered by our medical review team.
OSMITROL 15% IN WATER is a Osmotic Diuretic that works by Osmotic diuretic; increases plasma osmolality, drawing water from extravascular to intravascular space, thereby reducing intracranial and intraocular pressure.. MANNITOL 10% is a Osmotic Diuretic that works by Mannitol is an osmotic diuretic that increases urinary output by raising the osmolarity of glomerular filtrate, thereby reducing tubular reabsorption of water and solutes. It also reduces cerebral edema by creating an osmotic gradient across the blood-brain barrier, drawing water from brain tissue into plasma.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OSMITROL 15% IN WATER and MANNITOL 10% depend on the specific clinical indication. These are both Osmotic Diuretic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OSMITROL 15% IN WATER is: IV infusion of 50-200 g over 30-60 minutes as a 15% solution; typical adult dose is 1.5-2 g/kg every 6-8 hours.. The standard adult dose of MANNITOL 10% is: 0.25-2 g/kg intravenously as a 10% solution over 30-60 minutes, typically 50-100 g every 6-8 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OSMITROL 15% IN WATER and MANNITOL 10% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OSMITROL 15% IN WATER is classified as Category C. Osmitrol (mannitol) 15% in water is FDA pregnancy category C. Animal studies have not been conducted; no well-controlled human studies exist. Mannitol is a high-osmolar agent that . MANNITOL 10% is classified as Category A/B. Mannitol is a pregnancy category C drug. First trimester: Limited human data; animal studies indicate potential for fetal harm at high doses due to osmotic effects, but risk with c. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.